Tag: Relapsed FL options

Home / Relapsed FL options

Categories

Lisocabtagene maraleucel is granted accelerated approval by FDA for follicular lymphoma

May 2015:  Lisocabtagene maraleucel (Breyanzi, Juno Therapeutics, Inc.) has been granted rapid approval by the Food and Drug Administration. This approval is specifically for people with relapsed or ...
relapsed-fl-options

Scan the code